Results: A few studies have focused on the economic burden of type1 diabetes (T1DM). The aim of this study was to evaluate the resources consumption among adults with T1DM in Italy. During a routine visit, patients completed a questionnaire to retrospectively evaluate health care resources consumption (use of drugs, General Practitioner and specialist visits, hospitalizations, etc.). The time horizon was 12 months for hospital admissions and 3 months for all other items. In the context of a case-control study comparing patients treated with CSII with those on multiple daily injections, 62 diabetes clinics enrolled a total of 1193 consecutive patients (49.5% females). Mean age was of 35.2±11.8 years and average diabetes duration was of 16.1±11.8 years. Patients suffering from eye and renal complications were 24.8% and 8.0%, respectively, while those suffering from 1, 2, or ≥3 diabetes complications were 19.4%, 6.9%, and 4.3%, respectively. The costs were estimated with the assumption that 5% of DM1 patients were treated with CSII and 95% with MDI, based on national surveys. The average yearly cost per patient was € 2416 (€ 2297 for patients treated with MDI and € 6218 for those treated with CSII), with self-monitoring accounting for 36.1% of the overall costs (ranging from 31.5% to 46.3% on the basis of local prices of the strips). Drugs accounted for 25.7% (insulin 22.7%, other therapies 3.0%), diagnostic tests for 12.3%, and specialist visits for 11.2% (1.3% GPs, 9.9% specialist) of the costs; devices, assistance at home or travelling/lodging accounted for the 11.9% of the overall direct costs, while hospitalization was responsible for 2.1% of the costs.Average yearly cost raised according to the number and kind of complications, being of € 2232, € 2508, € 2880, and € 5064 for patients with no complications, 1, 2, ≥2 complications, and € 3132, € 2772 and € 3948 per patient with microvascular, macrovascular complications or both, respectively. Costs were directly correlated with diabetes duration (€ 2124, € 2412, € 2400, € 2772 for <5, 5-15, 15-25, >25 years, respectively) and level of HbA1c (€ 2388; € 2340; € 2532; € 2784 for HbA1c ≤7.0, 7.1-8.0, 8.1-8.9 and ≥9.0%, respectively). These results highlight the relevant economic burden of DM1, particularly in the presence of complications and poor metabolic control.

Direct Costs of Type I Diabetes in Adults in Italy

CAPANI, Fabio;VITACOLONNA, Ester;
2008-01-01

Abstract

Results: A few studies have focused on the economic burden of type1 diabetes (T1DM). The aim of this study was to evaluate the resources consumption among adults with T1DM in Italy. During a routine visit, patients completed a questionnaire to retrospectively evaluate health care resources consumption (use of drugs, General Practitioner and specialist visits, hospitalizations, etc.). The time horizon was 12 months for hospital admissions and 3 months for all other items. In the context of a case-control study comparing patients treated with CSII with those on multiple daily injections, 62 diabetes clinics enrolled a total of 1193 consecutive patients (49.5% females). Mean age was of 35.2±11.8 years and average diabetes duration was of 16.1±11.8 years. Patients suffering from eye and renal complications were 24.8% and 8.0%, respectively, while those suffering from 1, 2, or ≥3 diabetes complications were 19.4%, 6.9%, and 4.3%, respectively. The costs were estimated with the assumption that 5% of DM1 patients were treated with CSII and 95% with MDI, based on national surveys. The average yearly cost per patient was € 2416 (€ 2297 for patients treated with MDI and € 6218 for those treated with CSII), with self-monitoring accounting for 36.1% of the overall costs (ranging from 31.5% to 46.3% on the basis of local prices of the strips). Drugs accounted for 25.7% (insulin 22.7%, other therapies 3.0%), diagnostic tests for 12.3%, and specialist visits for 11.2% (1.3% GPs, 9.9% specialist) of the costs; devices, assistance at home or travelling/lodging accounted for the 11.9% of the overall direct costs, while hospitalization was responsible for 2.1% of the costs.Average yearly cost raised according to the number and kind of complications, being of € 2232, € 2508, € 2880, and € 5064 for patients with no complications, 1, 2, ≥2 complications, and € 3132, € 2772 and € 3948 per patient with microvascular, macrovascular complications or both, respectively. Costs were directly correlated with diabetes duration (€ 2124, € 2412, € 2400, € 2772 for <5, 5-15, 15-25, >25 years, respectively) and level of HbA1c (€ 2388; € 2340; € 2532; € 2784 for HbA1c ≤7.0, 7.1-8.0, 8.1-8.9 and ≥9.0%, respectively). These results highlight the relevant economic burden of DM1, particularly in the presence of complications and poor metabolic control.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/265054
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact